<DOC>
	<DOCNO>NCT01511874</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ELIGARD 22.5mg treatment subject prostate cancer .</brief_summary>
	<brief_title>Efficacy Safety Study ELIGARD 22.5mg With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Male 20 year Subject prostate cancer TNM stage T2~4NxMx Blood testosterone concentration ≥ 100ng/dl Bilirubin ≤ 1.5xULN , transaminase ≤ 2.5xULN WHO ECOG performance status ≤ 2 Signed write informed consent HormoneRefractory Prostate cancer Brain metastasis Another primary malignant tumor except prostate cancer Other condition opinion investigator preclude enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ELIGARD</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>